Sun Zhicheng, Wang Xiyang, Pang Xiaoyang
Department of Spine Surgery, Xiangya Hospital of Central South University, Changsha, People's Republic of China.
Hunan Engineering Laboratory of Advanced Artificial Osteo-Materials, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Drug Des Devel Ther. 2025 Mar 6;19:1585-1594. doi: 10.2147/DDDT.S508851. eCollection 2025.
Ischemia-reperfusion injury is a multi-tissue/organ susceptible and highly destructive disease. The complex pathological mechanisms of ischemia-reperfusion injury make its prevention and treatment highly challenging, and the development of novel drugs with pharmacological pleiotropy that can target multiple pathological mechanisms has become the focus of current drug research. Polydatin is a traditional Chinese medicine monomer with pleiotropic pharmacological effects, and existing research evidence suggests that polydatin has strong protective potential against ischemia-reperfusion injury. However, the mechanism of polydatin against ischemia-reperfusion injury is still unclear. In this review, the extensive pharmacological-pathological mechanism associations between polydatin and ischemia-reperfusion injury have been described from the perspectives of inflammatory response, oxidative stress, apoptosis, autophagy, ferroptosis, and cellular pyroptosis, which will provide references to the basic and applied research of polydatin in the field of ischemia-reperfusion injury.
缺血再灌注损伤是一种多组织/器官易感性且具有高度破坏性的疾病。缺血再灌注损伤复杂的病理机制使其预防和治疗极具挑战性，开发能够靶向多种病理机制的具有药理多效性的新型药物已成为当前药物研究的重点。白藜芦醇苷是一种具有多效药理作用的中药单体，现有研究证据表明白藜芦醇苷对缺血再灌注损伤具有强大的保护潜力。然而，白藜芦醇苷抗缺血再灌注损伤的机制仍不清楚。在这篇综述中，从炎症反应、氧化应激、细胞凋亡、自噬、铁死亡和细胞焦亡等角度描述了白藜芦醇苷与缺血再灌注损伤之间广泛的药理-病理机制联系，这将为白藜芦醇苷在缺血再灌注损伤领域的基础研究和应用研究提供参考。
